16.2 C
September 19, 2021

Roche Romania Diagnostics Division aims at RON 91 M-turnover in 2011

In 2010, Roche Romania’s Diagnostics Division reported a 10.2 pc rise in turnover, compared to the preceding year, at RON 86.9 M, consolidating its market leader position.

“2010 was the Diagnostics Division’s first full activity year on the Romanian market. It was a year during which we consolidated our team and portfolio and we are glad we managed to initiate solid collaboration relations with our partners. We hope we will manage to maintain the initial trend and to continue along the same line,” Harald Wolf, Country Manager for Roche Romania Diagnostics Division, stated, yesterday, in a press conference, referring to the Division’s 2010 results.

All the five activity domains of the division contributed to boosting sales, but the most significant contributions came from areas like Immunology, Blood Coagulation, Clinical Chemistry and Molecular Biology (Research), which led to a 14 pc-rise in sales. In 2010, the division launched tests and diagnosis equipment for infectious diseases, coagulation, cardiovascular diseases, diabetes, as well as equipment for research institutes. At the same time, partnerships were sealed with a number of private clinics and hospitals, which included fitting two large capacity fully-automated labs with high quality equipment and an innovative overall concept. Also, Roche Romania Diagnostics Division hired 28 people last year, getting to a team of 65 people, which enabled it to go beyond the initially set sales target in 2010.
For this year, Roche Romania Diagnostics Division, which celebrates, in 2011, two years since the launch on the Romanian market, aims at a RON 91 M-turnover, based on new product launches, the development of the private healthcare system and the screening programs to be run by the Ministry of Health.

At the same time, representatives of the Swiss company’s division announced the launch of cobas® 4800, a platform for molecular screening and the automated genotyping of the Human Papilloma Virus (HPV), which may be available at any point in Romania and which can already be purchased on the external markets, at prices ranging between EUR 40 and 80. On this occasion, Dr. Mihaela Badea, Managing Director of the Micomi Clinic, stated that Romania continues to rank first in Europe as regards cervical cancer death rates. “While European statistics indicate a prevalence of 22.3 pc of HPV at women with a normal cytology (4,053 cases tested), statistics in Romania remain incomplete. Nevertheless, the data centralised by the World Health Organization show that, out of 9.44 million Romanian women with cancer risk (the female population over 15), the annual number of cases amounts to 3,448, out of whom 2,094 die,” Dr. Badea stated. The molecular screening method, using cobas® 4800, targets 14 types of high-risk HPV, particularly genotypes 16 and 18.

Related posts

Deposits made by companies and population soar to RON 181 bln

Nine O' Clock

Barroso: Eurozone, in front of a systemic crisis

Nine O' Clock

Hungarian press: Daimler evaluates the costs of a factory in Romania

Nine O' Clock